Beta Bionics Hits 10,000 iLet Bionic Pancreas Users

Milestone Achievement

Beta Bionics has celebrated a major achievement: Beta Bionics has declared that its iLet bionic pancreas system has now been used by 10,000 patients. This system simplifies diabetes management by automating insulin delivery.

How the iLet System Works

The iLet system, developed in Concord, Massachusetts, is designed to make managing diabetes easier. It received FDA clearance in May 2023.

Adaptive and Automatic

The iLet uses an advanced, closed-loop algorithm that only needs the user’s body weight to start. This means users don’t have to set up insulin dosing parameters manually. The system handles all insulin calculations and adjustments automatically.

Simplified Diabetes Management

With iLet, users just input their weight. The system then takes care of the rest, eliminating the need for carb counting or insulin corrections. It even simplifies mealtime by allowing users to announce their meals instead of counting carbs. The system learns and adapts to individual insulin needs over time.

Expanded Options

Last year, Beta Bionics introduced the iLet with the Dexcom G7 continuous glucose monitor (CGM). Users can choose between the G7 or the earlier G6 model, or switch between them as needed.

Positive Impact and CEO’s Remarks

Sean Saint, CEO of Beta Bionics, commented on the milestone, saying, “Reaching 10,000 iLet Bionic Pancreas patients is a testament to our commitment to making diabetes easier for everyone, every day. By taking the work off their plate, we are empowering patients to live more freely with greater peace of mind.” He emphasized that the iLet system provides a more reliable and user-friendly approach to diabetes management compared to other devices.

Conclusion

Beta Bionics continues to focus on improving diabetes management. With the iLet system, they aim further to simplify the daily routines of people with diabetes, enhancing their quality of life. The company is excited about the ongoing impact and growth of its technology and remains dedicated to advancing diabetes care.